HF
SGMT icon

HRT Financial’s Sagimet Biosciences SGMT Stock Holding History

HRT Financial’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-27,211
Closed -$142K – 5227
2026
Q1 		$142K Buy
+27,211
New +$152K ﹤0.01% 3281
2025
Q3 		– Sell
-69,909
Closed -$532K – 3582
2025
Q2 		$532K Buy
+69,909
New +$295K ﹤0.01% 1574
2024
Q3 		– Sell
-70,548
Closed -$241K – 3055
2024
Q2 		$241K Buy
+70,548
New +$324K ﹤0.01% 1588

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

HRT Financial's SGMT Position: Q2 2026 in Review

HRT Financial sold out of Sagimet Biosciences (SGMT) in Q2 2026, closing a stake of 27,211 shares — an estimated $142K sold.

HRT Financial first reported a position in SGMT in Q2 2024 and held it in 3 quarters. The position peaked at $532K in Q2 2025. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • HRT Financial reported no remaining Sagimet Biosciences position as of Q2 2026 after selling out during the quarter.
  • HRT Financial sold 27,211 Sagimet Biosciences shares in Q2 2026, an estimated $142K.
  • HRT Financial first reported a position in Sagimet Biosciences in Q2 2024 and held it in 3 quarters.
  • HRT Financial's Sagimet Biosciences position peaked at $532K in Q2 2025.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.